Picture Berlin Partner Top News CareSyntax Raises $61m for Bio Cheese 650x100px

Document › Details

AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]".

	Region	ALL
	Organisation	AstraZeneca plc (LSE: AZN)
	Group	AstraZeneca (Group)
	Organisation 2	Eccogene (CN)
	Product	ECC5005 (Eccogene / AstraZeneca)
	Product 2	obesity drug
	Index term	AstraZeneca–Eccogene: GLP-1 receptor agonist, 202311– license ww excl $185m upfront + $1.825b milestones + royalties for ECC5004
	Person	Barr, Sharon (AstraZeneca 202311 EVP BioPharmaceuticals RnD)
	Person 2	Zhou, Jingye (Eccogene 202311 CEO + Co-Founder before Lilly + GSK + Tetraphase Pharmaceutical)

Original document
accessed by [iito] on 2023-11-21

Record changed: 2024-03-14

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x200px

More documents for AstraZeneca (Group)

[1] Qiagen N.V.. (8/28/24). "Press Release: Qiagen Expands QIAstat-Dx into Precision Medicine through Partnership for Companion Diagnostics in Chronic Diseases". Venlo....
[2] Pinetree Therapeutics, Inc.. (7/23/24). "Press Release: Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca". Cambridge, MA....
[3] Huma Therapeutics Ltd.. (7/16/24). "Press Release: Huma Completes Series D with Total Financing of over $80m as It Launches Huma Cloud Platform with GenAI Integrations to Bring Digital First Care and Research to Everyone". London & New York, NY....
[4] AstraZeneca plc. (3/19/24). "Press Release: AstraZeneca to Acquire Fusion to Accelerate the Development of Next-generation Radioconjugates to Treat Cancer"....
[5] Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA....
[6] Allorion Therapeutics Inc.. (1/2/24). "Press Release: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca". Natick, MA....
[7] Gracell Biotechnologies Inc.. (12/26/23). "Press Release: Gracell Biotechnologies to Be Acquired by AstraZeneca, furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases". San Diego, CA, Suzhou & Shanghai....
[8] AstraZeneca plc. (12/26/23). "Press Release: AstraZeneca to Acquire Gracell, Furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases"....
[9] AstraZeneca plc. (12/12/23). "Press Release: AstraZeneca to Acquire Icosavax, Including Potential First-in-Class RSV and hMPV Combination Vaccine with Positive Phase II Data"....
[10] Icosavax, Inc.. (12/12/23). "Press Release: Icosavax, Inc. Announces Agreement to Be Acquired by AstraZeneca". Seattle, WA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]